3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
59
Carcinoma, Hepatocellular
43
Colorectal Neoplasms
32
Stomach Neoplasms
28
Esophageal Squamous Cell Carcinoma
27
Squamous Cell Carcinoma of Head and Neck
20
Esophageal Neoplasms
14
Small Cell Lung Carcinoma
13
Neoplasm Metastasis
13
Lung Neoplasms
13
Head and Neck Neoplasms
12
Advanced Solid Tumor
12
Cholangiocarcinoma
11
Triple Negative Breast Neoplasms
10
Rectal Neoplasms
10
Nasopharyngeal Carcinoma
10
Melanoma
10
Uterine Cervical Neoplasms
9
Recurrence
9
Neoplasms
9
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Urinary Bladder Neoplasms
6
Solid Tumor
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Sarcoma
5
Lymphoma, Extranodal NK-T-Cell
5
Lymphoma
5
Hodgkin Disease
5
Interventions
pembrolizumab
7
lenvatinib
3
apatinib
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Carboplatin
3
gallium 68 PSMA-11
2
Specimen Handling
2
Protons
2
Nivolumab
2
Epirubicin
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tislelizumab
1
regorafenib
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tretinoin
1
Trastuzumab
1
Tablets
1
Sunitinib
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Adenoid Cystic
×
tislelizumab
×
Clear all
NCT03287427
2023-02-15
MYPHISMO
Peter MacCallum Cancer Centre, Australia
Phase 1
Completed
27 enrolled